Why Abeona Therapeutics Inc. Is Surging Today

This post was originally published on this site

What happened

Shares of Abeona Therapeutics (NASDAQ:ABEO), a clinical-stage biotech focused on rare diseases, rose by 16% as of 3:55 p.m. EDT on Tuesday.

So what

The company announced that the European Medicines Agency has granted its lead gene therapy compound, ABO-102, orphan-drug status. ABO-102 is currently in phase 1/2 testing as a hopeful treatment for Sanfilippo syndrome type A, a potentially deadly rare autosomal disease that results in abnormal accumulation of sugars in the body. 

Receiving orphan-drug designation provides the company with a number of potential benefits, including lower regulatory fees, increased guidance from regulatory agencies, and a longer protection period from competition if it wins approval.

The news caused a handful of analysts to reaffirm their “buy” rating on the company, which is why shares are moving higher today.

Now what

Abeona currently has two product candidates in development — ABO-101 and ABO-102 — for Sanfilippo syndromes, and the FDA has already granted an orphan-product and rare pediatric disease designation to both. If the company manages to win approval for either, then it could earn pediatric disease priority review vouchers, allowing the company to cut the review time of another one of its drugs to six months from the standard 10-month period. Another option could be to sell the voucher on the open market, which could be a great way to raise capital without diluting shareholders. 

There’s no doubt that Abeona’s future is looking bright if either one of its product candidates can find its way to market, but it’s important to remember that both of them are still in early clinical development. That means there are still plenty of hurdles for the company to clear before it can start to generate product revenue. For that reason, only investors with an extremely high tolerance for risk should consider making an investment today.

Brian Feroldi has no position in any stocks mentioned. Like this article? Follow him on Twitter, where he goes by the handle @Longtermmindset, or connect with him on LinkedIn to see more articles like this.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Be Sociable, Share!

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.